Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Differ
Asıl Yazarlar: Kramer, Daniela, Stark, Nadine, Schulz-Heddergott, Ramona, Erytch, Norman, Edmunds, Shelley, Roßmann, Laura, Bastians, Holger, Concin, Nicole, Moll, Ute M, Dobbelstein, Matthias
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2017
Konular:
Original Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299713/
https://ncbi.nlm.nih.gov/pubmed/27834954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.124
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller